Aardvark Therapeutics Securities Fraud Class Action
Analysis based on 176 articles · First reported Aug 14, 2026 · Last updated Sep 23, 2026
The revelations of safety concerns and the FDA clinical hold have severely impacted Aardvark's stock, which fell approximately 71.4% from its IPO price. The securities class actions add legal and financial uncertainty, potentially leading to significant settlement costs and further reputational damage for the company.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, is facing multiple securities fraud class action lawsuits filed by several law firms on behalf of investors who purchased shares in its February 13, 2025 IPO or during the Class Period from February 13, 2025 to May 14, 2026. The lawsuits allege that the company and certain officers made false and misleading statements and failed to disclose that its lead drug candidate, ARD-101, was less safe than represented, leading to overstated clinical, regulatory, and commercial prospects. The alleged safety issues came to light on February 27, 2026, when Aardvark voluntarily paused its Phase 3 HERO trial due to reversible cardiac observations at above-target doses, causing its stock to plummet over 56%. On May 14, 2026, the United States — Food and Drug Administration placed a full clinical hold on the ARD-101 investigational new drug application, halting all ongoing studies, and the stock fell another 32.1%. The lawsuits seek damages for investors who suffered losses, with a lead plaintiff deadline of October 13, 2026. The case is filed in the United States District Court for the Southern District of California.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard